John T. Cavan serves as Executive at ContraVir Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, John T. Cavan has executed 5 insider transactions totaling $40.3K, demonstrating a bullish approach to their equity position. Their most recent transaction on Feb 18, 2021 involved purchasing 10,000 shares valued at $20.0K.
John T. Cavan currently holds 14,800 shares of ContraVir Pharmaceuticals, Inc. (CTRV), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, John T. Cavan has been a net buyer of CTRV stock. They have purchased $40.3K and sold $0 worth of shares.
John T. Cavan's most recent insider trade was on Feb 18, 2021, when they purchased 10,000 shares at $2.00 per share.
Get notified when new Form 4 filings are submitted
| $1.62 |
| Discretionary |
| Jan 3, 2018 | CTRV | $0 | Award | 101,221 | $N/A | Discretionary |
| Jul 6, 2017 | CTRV | $0 | Award | 46,726 | $N/A | Discretionary |
| Jun 20, 2017 | CTRV | $13.0K | Purchase | 20,000 | $0.65 | Discretionary |